Skip to content
MatchScript
Menu

Head-to-head · The Match Score

CoreAge Rx vs Youth & Soul

Both scored on the same six-factor Match Score. CoreAge Rx wins this matchup with a 91 to 60 edge.

Higher Match Score

CoreAge Rx

#1 · Grade A−

Anyone who wants transparent flat pricing, fast nationwide access, and no teaser-rate bait-and-switch.

Visit CoreAge Rx
VS

Youth & Soul

#309 · Grade C

Shoppers who want many treatment categories in one account and are willing to verify claims themselves.

Visit Youth & Soul

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
72
Speed to Start
97
50
Formulary Match
80
72
Support Level
93
50
Flexibility
97
49
Transparency
95
66

Price, coverage & formulary

DetailCoreAge RxYouth & Soul
Semaglutide$149/mo$149/mo (starting dose, compounded)
Tirzepatide$349/mo$399/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjectable onlyInjectable only
Match Score91 · A−60 · C
Winner: CoreAge Rx

CoreAge Rx is our #1-ranked provider overall, and it takes this matchup too — a 91 Match Score to Youth & Soul's 60. The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.

Youth & Soul is still a fair pick if its strengths line up with yours — best for: Shoppers who want many treatment categories in one account and are willing to verify claims themselves.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full CoreAge Rx reviewFull Youth & Soul review

More head-to-heads

Or browse alternatives to CoreAge Rx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.